| abstract |
The present invention provides a method for evaluating a candidate substance for an anticancer drug, which can be evaluated more reflecting the clinical pathology than conventional methods. A method for evaluating an anticancer drug candidate substance using a rat as a non-human mammal cancer-bearing model animal, comprising the steps of evaluating the pharmacology of the anticancer drug candidate substance, evaluating the pharmacokinetics, and evaluating the safety This is a method for evaluating an anticancer drug candidate substance, which is performed in rats of the same individual. It is preferred that the rat is immunodeficient or immunocompromised. [Selection] Figure 1 |